Madrigal May Shake Up NASH Race With Phase II Resolution Data

Throwing a potential upset in the emerging non-alcoholic steatohepatitis (NASH) market, Madrigal Pharmaceuticals Inc.’s selective thyroid hormone receptor beta agonist reported Phase II data May 31 that surpass trial results for other NASH candidates, showing that MGL-3196 can resolve NASH and that 12-week liver fat-reduction data correlate to 36-week histologic improvements in NASH patients.

Although four other companies already have begun Phase III work in NASH and nothing Madrigal can do will position MGL-3196...